Vortioxetine Hydrobromide Tablets

DRUG2 trials

Sponsors

Seasons Biotechnology (Taizhou) Co., Ltd., Chengdu Kanghong Pharmaceutical Group Co., Ltd.

Conditions

Major Depressive Disorder (MDD)

Phase 1

Single Dose Oral Bioequivalence Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets

CompletedNCT05417087

Seasons Biotechnology (Taizhou) Co., Ltd.Major Depressive Disorder (MDD)

Start: 2022-06-27End: 2022-09-02Updated: 2023-04-13

Phase 3

Compare the Efficacy and Safety of KH607 Tablets Versus Vortioxetine Hydrobromide Tablets in Adult Patients With Major Depressive Disorder

Not yet recruitingNCT07741331

Chengdu Kanghong Pharmaceutical Group Co., Ltd.Major Depressive Disorder (MDD)

Start: 2026-07-01End: 2028-12-01Target: 326Updated: 2026-08-03